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Abstract
Esophageal cancer has an aggressive behavior with rapid tumor mass growth and frequently poor prognosis; it is known 
as one of the most fatal types of cancer worldwide. The identification of potential molecular markers that can predict the 
response to treatment and the prognosis of this cancer has been subject of a vast investigation in the recent years. Among 
several molecules, various angiogenic factors that are linked to the tumor development, growth, and invasion, such as VEGF, 
HGF, angiopoietin-2, IL-6, and TGF-B1, were investigated. In this paper, the authors sought to review the role of these 
angiogenic factors in prognosis and hypothesize how they can be used as a treatment target.
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Introduction
Esophageal cancer has an aggressive tumor growth and poor 
prognosis and a 5-year overall survival rate between 15 and 
25% [1]. It is one of the most fatal types of cancer world-
wide. For esophageal squamous cell carcinoma (SCC), the 
overall 5-year survival rate is ~ 20% [2]. The identification 
of potential molecular markers that can predict the response 
to treatment and the prognosis of the disease has been sub-
ject of a vast investigation in the last years.
Various studies indicated that factors that shape the tumor 
microenvironment might influence patient’s response and 
outcome. An inflammatory reaction promotes tumor prolifer-
ation, invasion, and angiogenesis [3]. Beyond a certain size, 
tumors are not further supported by diffusion, but undergo 
“an angiogenic switch” which supports further tumor growth 
and metastasis, with formation of new blood vessels within 
the tumor [4]. Based on that, various cytokines, including 
interleukin (IL)-6, IL-8 and tumor necrosis factor (TNF)-α, 
are critical in the pathogenesis of numerous cancers. In par-
ticular, IL-6 serum levels have been reported to be elevated 
in patients with esophageal carcinoma [5], but its role in 
this cancer remains unclear. IL-6 plays a vital role in cell 
proliferation, migration, invasion, apoptosis, angiogenesis, 
growth, and differentiation of cancer cells [6]. Other angio-
genic factors involved are vascular endothelial growth fac-
tor (VEGF), hepatocyte growth factor (HGF), and fibroblast 
growth factor (FGF) [7]. Several studies indicate that HGF 
is over-expressed in squamous cell carcinoma (SCC) tissue 
specimen and serum levels are associated with survival and 
clinicopathological parameters such as distant metastases 
[8]. Another angiogenic factor associated with poor sur-
vival is FGF [9]. Other studies have suggested an important 
role of the hypoxia-inducible factor-1 (HIF-1) as an inducer 
for angiogenic factors in hypoxic tumor microenvironment 
[10]. Among genes whose expression is regulated by HIF-1, 
VEGF is well documented as a key angiogenic factor [11]. 
Correlation of expression of these two factors with clinical 
outcome has been widely investigated in a variety of human 
cancers including esophageal cancer [12].
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This paper reviews the role of angiogenic factors involved 
in development, growth, and proliferation of esophageal can-
cer, as well as their role in prognosis and, ultimately, how 
can they be used as a specific target for treatment.
Materials and methods
A PubMed research was realized focusing angiogenesis 
in esophageal cancer. The Mesh database with the terms: 
“Esophageal cancer/angiogenesis [mesh] and angiogenic 
factors/esophageal neoplasms [mesh]” was used.
A total of 30 articles were collected. Five articles were 
excluded from this review, because they studied the most 
suitable compartment for the assessment of the various angi-
ogenic factors and did not study the molecule itself.
Results and discussion
Hepatocyte growth factor
HGF and its receptor c-Met play an important role in the 
development of various cancer types. It is a growth factor 
directed to epithelial cells that is important in embryogen-
esis and mediates defense to tissue damage in adults; HGF 
stimulation of vascular endothelial cells promotes migration, 
proliferation, protease production, invasion, and organiza-
tion into capillary-like tubes. It binds c-Met (tyrosine kinase 
receptor) as exclusive ligand induces the activation of onco-
genic pathways, angiogenesis, and scattering of cells, lead-
ing to metastasis [13].
The Met gene encodes the tyrosine kinase receptor for 
hepatocyte growth factor (HGF)/scatter factor (SF), and 
exposure of Met-expressing cells to this lead to prolifera-
tion, migration, invasion, and branching morphogenesis 
[14]. Numerous studies have shown that HGF/SF-Met is 
involved in esophageal SCC. Ren et al. [15] found that there 
was no significant correlation between serum HGF concen-
tration and patients’ gender, age, and tumor and node stage, 
in SCC. However, serum HGF levels were significantly 
higher in patients with M1a/b disease, and patients whose 
tumor was at stage III or IV also had higher HGF level com-
pared with those who had stage I or II disease. The median 
survival of patients with low serum HGF levels (n = 75) 
was 34.7 months, and was significantly better than that 
of patients with high HGF levels (n = 74) at 15.8 months 
(P = 0.014); respective 2-year survival figures were 63.5 
versus 37.0%. The data also showed that HGF increased 
the secretion of other angiogenic factors, as VEGF and 
IL-8, in a dose-dependent manner. HGF-induced IL-8 and 
VEGF expression was found to be dependent on extracel-
lular signal-regulated kinase (ERK) signaling pathways. The 
inhibition of ERK activation reduced HGF-induced IL-8 and 
VEGF expression, suggesting that this pathway is important 
in HGF-mediated production of angiogenic factors. Overex-
pression of c-Met was reported by Saeki et al. [16] in ESCC 
tumor cells and cell lines. These results provide a foundation 
for the hypothesis that HGF participates in angiogenesis via 
autocrine/paracrine mechanisms.
Angiopoietin‑2/follistatin
Angiopoietin-2 is a critical regulator of tumor angiogen-
esis. Studies have shown a significant correlation of Angi-
opoietin-2 expression to tumor invasion and metastasis in 
various human cancers, but little is known about the serum 
Angiopoietin-2 levels in esophageal squamous cell cancer 
(ESCC) and its precursors. Zhou et al. investigated the role 
of Angiopoietin-2 in screening for ESCC and its precursors. 
The authors reported that serum Angiopoietin-2 levels were 
22.0 ± 5.5 in normal group, (21.3 ± 3.2) in esophagitis, 
20.5 ± 3.3 in hyperplasia, 24.0 ± 5.0 in early ESCC, and 
29.8 ± 5.0 U/ml in invasive ESCC group; it was signifi-
cantly higher in the early ESCC than in hyperplasia group 
(P = 0.009), and the highest level was observed in inva-
sive ESCC group (P = 0.000). The sensitivities of serum 
Angiopoietin-2 to early and invasive ESCC were 23.1 and 
78.6%, respectively. Therefore, the authors concluded that 
serum Angiopoietin-2 level is related to carcinogenesis and 
progression of ESCC, but it cannot be used to screen for 
early ESCC [17].
Dreikhausen et al. [18] reported a retrospective explora-
tory study to verify the association of angiogenic factors 
with prognosis in esophageal SCC and adenocarcinoma 
of the esophagogastric junction (AEG). In this study, the 
levels of most angiogenic factors in AEG and SCC were 
similar, but the differences of these two entities with respect 
to angiogenesis were indicated by the different expression 
of Angiopoietin-2 and Follistatin. They found significant 
higher median tissue levels of the two angiogenic factors in 
SCC patients as compared to AEG patients. Furthermore, 
they can be correlated with other angiogenic factors—high 
HGF and Follistatin expression in the tumor tissue were 
associated with poor patient’s prognosis.
IL‑6
IL-6 is one of the most dysregulated cytokines in cancer, 
acting to inhibit cell apoptosis and accelerating angiogenesis 
by the activation of KAK/STAT3 and PI3K/AKT signaling 
pathways [3]. STAT3 plays an important role in tumor pro-
gression, behavior, and epithelial–mesenchymal transition 
(EMT)-associated changes [19].
Zhao et al. [20] demonstrated that cancerous cells of 
esophageal SCC expressed significantly higher levels of IL-6 
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when compared with normal epithelia (P = 0.0021). It was 
used an IL-6 silencing vector and it was observed that it sig-
nificantly reduced the proliferation of the two cell lines used 
in this study compared with the control-vector-transfected 
cells (P = 0.0013) and, in addition, the silencing vector sig-
nificantly attenuated the growth of tumors in the xenograft 
mouse models (P = 0.0031); furthermore, marked inhibition 
of tumor invasion was observed in the IL-6 silenced vector 
group in the two tumor models. It was hypothesized that 
IL-6 has a direct role or indirect role in angiogenesis and 
esophageal cancer progression. By inhibiting IL-6, tumor 
growth was found to be significantly inhibited in vitro and 
in vivo, and tumor growth and invasive ability was signifi-
cantly attenuated (P < 0.05). In addition, the IL-6 silencing 
vector markedly reduced the presence of Ki-67 (an impor-
tant proliferation marker) and microvessel density, indicating 
that down-regulation may affect tumor growth and inhibi-
tion; it also increased E-cadherin and matrix metallopro-
teinase (MMP)-9 expressions, and reduced the secretion of 
vascular endothelial growth factor (VEGF) and cluster of 
differentiation (CD)-31 (a nuclear protein), that mediated 
endothelial cell–cell interactions and actively participated in 
angiogenesis. These results indicated that EMT-associated 
changes and angiogenesis are interrelated and involved in 
aggressive tumor growth in esophageal cancer.
Many studies suggested that IL-6 provides a suitable 
in vivo environment for the growth and development of 
tumor cells, and reported that it may lead to resistance to 
certain anticancer drugs by promoting angiogenesis and cell 
mobility [21].
The hypothesis that IL-6 may be an important trigger in 
the progression of angiogenesis and endothelial tube forma-
tion within the tumor is well described, and IL-6 may be 
a promising target for the treatment of esophageal cancer.
VEGF/HIF‑1
HIF-1 is a heterodimeric basic helix–loop–helix protein 
composed of HIF-1α and HIF-1β subunits [22]. Under nor-
moxic conditions, the HIF-1α subunit is subjected to ubiquit-
ination and proteasomal degradation, whereas in hypoxia, its 
degradation is inhibited, and its expression increases rapidly 
[23]. Tumors derived from cells lacking HIF-1α or HIF-1β 
show significantly reduced vascularization and often reduced 
growth rates compared with parental cells [24]. A key angio-
genic factor whose gene expression is regulated by HIF-1 is 
the vascular endothelial growth factor (VEGF) [11]. VEGF 
is a family of the platelet-derived growth factor composed of 
6 VEGF members including VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, and placenta growth factor (PIGF) [25]. 
Under hypoxic conditions within the tumor cells, HIF-1α 
binds to a DNA recognition sequence in the promoter of 
target genes, including the VEGF gene [26]. Thus, under 
hypoxic conditions, VEGF transcription is up-regulated by 
HIF, and in addition, hypoxia promotes the stabilization of 
VEGF mRNA by proteins that bind to sequences in the 3′ 
untranslated region (3′ UTR) of the mRNA [27]. The prog-
nostic significance of VEGF expression has been reported in 
gastric, colon, breast, bladder, and esophageal carcinomas, 
as well as in other malignancies [28]. The previous studies 
for gastrointestinal malignancies have focused on expres-
sion of VEGF-C in relation to lymph node metastasis and 
survival, including gastric, esophageal, and colorectal carci-
nomas [29]. Inhibition of HIF-1α results in down-regulation 
of VEGF and increased apoptosis of cancer cells, indicat-
ing that HIF-1α may serve as a potential target for cancer 
therapy while supporting its role as a key factor in tumor 
angiogenesis and tumor progression. HIF-1α is absent in 
most normal tissues [30].
Recent studies have shown that HIF-1α expression cor-
relates with VEGF expression and high expression of these 
two factors is generally considered as poor prognostic pre-
dictors in various human cancers including esophageal 
cancer. Kimura et al. reported a 39% of high expression of 
HIF-1α in 32 out of their 82 ESCC tumor specimens and 
concluded that higher expression of HIF-1α correlated posi-
tively with vascular invasion and microvessel density within 
the tumor but not tumor stage, individual TNM factors, or 
survival for the entire patient cohort [31]. In contrast, Tzao 
et al. showed a higher rate of high HIF-1α expression, 52 in 
85 (61.2%), of resected tumor specimens; the expression of 
HIF-1α correlated positively with tumor stage and inversely 
with patients’ survival. They speculate that preoperative 
induction therapy may alter HIF-1 α expression in ESCC 
[32].
The previous studies rarely investigated relationship 
between expression of HIF-1α and VEGF-D in the same 
series. Expression of HIF-1α is associated with that of 
VEGF-C in ESCC and both of these two factors predict 
patient’s survival [33]. Tzao et al. have also demonstrated 
that expression of VEGF-D, relative to VEGF-C, was also 
associated with expression of HIF-1α in resected ESCC, 
for which supported by a significant concordance (69.5%) 
between expression of HIF-1α and VEGF-D. Taken together, 
these results may imply that different types of VEGF may 
function synergistically with HIF-1α in promoting tumor 
angiogenesis. However, author reveals that this speculation 
needs further investigation on their gene expression and 
biological functions in relation to tumor angiogenesis using 
in vitro and/or in vivo models [34].
The identification of selective HIF-1 inhibitors would not 
only be useful for the potential therapeutic implications but 
also for their application as analytic tools to further define 
the role of HIF in human cancers. Continued efforts have 
been made in the development of HIF inhibitors, such as 
synthetic polyamides, that inhibit HIF-1 DNA binding [35], 
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and more recently, it was identified small molecule inhibi-
tors (e.g., 103D5R) that selectively blocks HIF-1 protein 
synthesis [34]. On the other hand, bevacizumab, an anti-
VEGF monoclonal antibody, has been proven to be an use-
ful target therapy option in a variety of cancers [35], and 
ramucirumab (a VEGFR-2 inhibitor that prevents VEGF 
binding in endothelial cells) is actually recommended by 
the National Comprehensive Cancer Network (NCCN) as 
a second-line therapy for metastatic esophageal adenocar-
cinoma [36].
TGF‑β1
Cytokines of the transforming growth factor (TGF)-β super-
family are multifunctional proteins that regulate a variety of 
biological processes, including cell growth, differentiation, 
apoptosis, and morphogenesis [37], inhibiting epithelial 
cell proliferation. Loss of the growth-inhibitory response 
to TGF-β is found in many tumor cells [38] and the excess 
TGF-β that results to this sensibility loss may act on tumor 
cells and stromal cells to facilitate invasion and metastasis 
[39]. In tumors, it acts early in carcinogenesis as a tumor 
suppressor but acts later as a stimulator of tumor invasion 
by prompting extracellular matrix production and angio-
genesis, stimulating tumor proliferation, and inhibiting host 
immune functions. Loss or resistance of this inhibitory 
effect to TGF-β has been reported in many tumor cells and 
elevated systemic TGF-β1 levels have been reported in vari-
ous cancers [40–45], as well as increased local TGF-β1 has 
been observed in many cancer cells [47]. Local expression of 
TGF-β1 was related to tumor progression in esophageal can-
cer, in contrast to systemic TGF-β1 level [43]. It is known 
that plasma TGF-β1 level may be influenced by systemic 
inflammation or a chronic disease, and TGF-β1 may be 
secreted from normal tissues as well as tumors.
In a study, plasma TGF-β1 level was obtained from 
venous blood of the azygos vein instead of a peripheral vein 
and was measured and correlated with pathological findings 
and survival of patients with esophageal cancer. The azygos 
vein is responsible for venous return from the esophagus, 
and his level of plasma TGF-β1 may reflect tumor progres-
sion and condition more directly and accurately than the 
TGF-β1 level in other veins [47]. Plasma for normal con-
trols could not be obtained from the azygos vein of healthy 
volunteers, so it was used the mean value measured from 
peripheral veins [43]. A significant correlation between the 
TGF-β1 level measured from the azygos vein and metastasis 
to distant lymph nodes in esophageal cancer (P = 0.0396) 
was observed, suggesting that elevated TGF-β1 exhibits the 
effects of angiogenesis, extracellular matrix production, and 
immune suppression, contributing to tumor development 
and metastasis to distant lymph nodes [48]. It was observed 
that the survival rates of patients with high TGF-β1 levels 
(levels above the mean value of healthy controls) were sig-
nificantly lower than those of patients with low TGF-β1 lev-
els (P = 0.0317) and the TGF-β1 level measured from the 
azygos vein was an independent prognostic factor of overall 
survival (P = 0.0474). According to these results, the TGF-
β1 level in the azygos vein may reflect tumor condition and 
viability more appropriately than local expression does. 
High TGF-β1 levels predict poor prognosis in patients who 
would eventually have cancer recurrence in lymph nodes or 
other organs. The authors concluded that the level of plasma 
TGF-β1 measured from the azygos vein is a useful prognos-
tic marker in patients with esophageal cancer, but further 
studies with more patients and follow-up those for longer 
periods will be needed.
Fibroblast growth factor
The expression of basic fibroblast growth factor (b-FGF) in 
squamous cell carcinoma of the esophagus was immuno-
histochemically investigated in tissue specimens from 79 
patients with squamous cell carcinoma of the esophagus 
who underwent curative esophagectomy without preopera-
tive chemotherapy or radiation therapy. Tumor cells that 
expressed b-FGF were found in 41 patients (51.9%). The 
mean vascular density of b-FGF-positive tumors (47.9/mm2) 
was significantly lower than that of b-FGF-negative tumors 
(67.2/mm2) (P = 0.014), and the survival rate of patients 
with b-FGF-positive tumors was significantly higher than 
those with b-FGF-negative tumors (P = 0.033). The authors 
concluded that the expression of b-FGF may be associated 
with promotion of angiogenesis and a good candidate as a 
prognostic factor in squamous cell carcinoma of the esopha-
gus [49] (Fig. 1).
Conclusion
Angiogenesis is essential for tumor growth and its spread, 
including invasion and metastasis. However, rather than 
being controlled by means of a simple mechanism, the con-
trol of tumor angiogenesis may be mediated by several angi-
ogenic factors. HGF, VEGF, HIF-1, IL-6, FGF, TGF-B1, 
angiopoietin-2, and follistatin are some of these factors, with 
several studies demonstrating their importance in esophageal 
cancer, mainly in squamous cell carcinoma of the esophagus. 
The best studied angiogenic factor is VEGF, with several 
studies in the literature. It also seems to be the most impor-
tant in the prognosis of patients with esophageal cancer. In 
the REGARD trial, it was recently shown that treatment 
with an antibody against VEGF receptor 2 (VEGFR-2) in 
monotherapy, ramucirumab, can prolong survival in patients 
with advanced gastric and esophageal cancer. However, it is 
also known that other angiogenic factors have an important 
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role in cancer development and progression, like IL-6, HGF, 
angiopoietin-2, and TGF-B1. These can be used as prognos-
tic markers but, more importantly, as potential therapeutic 
targets. However, it is consensual that more studies and trials 
are needed.
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